{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:21:34Z","timestamp":1791584494492,"version":"4.3.4"},"reference-count":96,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jaip.2025.02.006","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T12:54:22Z","timestamp":1739883262000},"page":"1057-1067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Severe Cutaneous Adverse Reactions Following Vaccination: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9394-4144","authenticated-orcid":false,"given":"Kevin Sheng-Kai","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Hsuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Han","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly G.","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.02.006_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-024-00514-0","article-title":"Severe cutaneous adverse reactions","volume":"10","author":"Hung","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaip.2025.02.006_bib2","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/1346-8138.13430","article-title":"Severe cutaneous adverse drug reactions","volume":"43","author":"Chung","year":"2016","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40257-020-00505-3","article-title":"Fixed drug eruptions: an update, emphasizing the potentially lethal generalized bullous fixed drug eruption","volume":"21","author":"Patel","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jaad.2015.07.017","article-title":"Acute generalized exanthematous pustulosis (AGEP): a review and update","volume":"73","author":"Szatkowski","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jaad.2023.02.072","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis","volume":"90","author":"Wei","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2025.02.006_bib96","article-title":"et al., External validation study of Re-SCORTEN in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"26","author":"Westmeijer","year":"2024","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib7","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaip.2022.02.004","article-title":"Drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis","volume":"10","author":"Hama","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.006_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/cod.14075","article-title":"Results of patch testing in acute generalized exanthematous pustulosis (AGEP): a literature review","volume":"87","author":"de Groot","year":"2022","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2025.02.006_bib9","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/ijd.14409","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience","volume":"58","author":"Zhang","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1517\/14740338.2016.1167869","article-title":"Adverse events following immunization: real causality and myths","volume":"15","author":"Principi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaip.2025.02.006_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaci.2012.04.003","article-title":"Adverse reactions to vaccines practice parameter 2012 update","volume":"130","author":"Kelso","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.02.006_bib12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.clindermatol.2014.12.009","article-title":"Cutaneous reactions to vaccinations","volume":"33","author":"Rosenblatt","year":"2015","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1440-0960.2011.00845.x","article-title":"Acute generalised exanthematous pustulosis","volume":"53","author":"Fernando","year":"2012","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib94","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/bjophthalmol-2020-317105","article-title":"Human leucocyte antigen association of patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis with severe ocular complications in Han Chinese","volume":"106","author":"Ma","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jaip.2025.02.006_bib95","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jtos.2021.06.010","article-title":"Ocular manifestations of anti-neoplastic immune checkpoint inhibitor-associated Stevens-Johnson syndrome\/toxic epidermal necrolysis in cancer patients","volume":"22","author":"Ma","year":"2021","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jaip.2025.02.006_bib97","doi-asserted-by":"crossref","first-page":"1137637","DOI":"10.3389\/ftox.2023.1137637","article-title":"Ocular surface complications following biological therapy for cancer","volume":"5","author":"Ma","year":"2023","journal-title":"Front Toxicol"},{"key":"10.1016\/j.jaip.2025.02.006_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jaip.2025.02.006_bib15","article-title":"Patients with suspected severe adverse reactions to COVID-19 vaccination admitted to intensive care unit: a case report","volume":"9","author":"Battaglini","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2025.02.006_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaad.2021.09.002","article-title":"Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry-based study","volume":"86","author":"McMahon","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/qjmed\/hcac282","article-title":"mRNA-1273 COVID-19 vaccine\u2013induced Steven-Johnson syndrome","volume":"116","author":"Lo","year":"2023","journal-title":"QJM"},{"key":"10.1016\/j.jaip.2025.02.006_bib18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10875-022-01408-0","article-title":"Macrophage activation syndrome complicated by toxic epidermal necrolysis following SARS-CoV-2 mRNA vaccination","volume":"43","author":"Franzblau","year":"2023","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2025.02.006_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/8855665","article-title":"Toxic epidermal necrolysis after COVID-19 mRNA-1237 vaccination","volume":"2023","author":"Hehr","year":"2023","journal-title":"Case Reports Immunol"},{"key":"10.1016\/j.jaip.2025.02.006_bib20","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/ijd.16222","article-title":"Stevens-Johnson syndrome precipitated by Moderna Inc. COVID-19 vaccine: a case-based review of literature comparing vaccine- and drug-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"61","author":"Padniewski","year":"2022","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jdcr.2021.08.013","article-title":"Acute generalized exanthematous pustulosis induced by Moderna COVID-19 messenger RNA vaccine","volume":"16","author":"Agaronov","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaip.2025.02.006_bib22","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v101.443","article-title":"Acute generalized exanthematous pustulosis in close temporal association with mRNA-1273 Vaccine","volume":"101","author":"Mitri","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2025.02.006_bib23","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1111\/1346-8138.16541","article-title":"Overlapping acute generalized exanthematous pustulosis drug reaction with eosinophilia and systemic symptoms induced by a second dose of the Moderna COVID-19 vaccine","volume":"49","author":"Ikeda","year":"2022","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib24","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/1346-8138.16347","article-title":"Three cases of drug-induced hypersensitivity syndrome associated with mRNA-based coronavirus disease 2019 vaccines","volume":"49","author":"Korekawa","year":"2022","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib25","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jiph.2021.06.021","article-title":"Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: case report","volume":"14","author":"Kong","year":"2021","journal-title":"J\u00a0Infect Public Health"},{"key":"10.1016\/j.jaip.2025.02.006_bib26","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1111\/jdv.18777","article-title":"Drug reaction with eosinophilia and systemic symptoms syndrome (DRESS) associated with pancreatitis and hepatitis following Pfizer-BioNTech mRNA COVID-19 vaccination","volume":"37","author":"Gamonal","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.02.006_bib27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.clindermatol.2022.02.018","article-title":"A\u00a0definite case of drug reaction with eosinophilia and systemic symptoms (DRESS) induced by administration of the Pfizer\/BioNTech BNT162b2 vaccine for SARS-CoV2","volume":"40","author":"Schroeder","year":"2022","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib28","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1016\/j.jaip.2021.07.012","article-title":"Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19","volume":"9","author":"Ju\u00e1rez Guerrero","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.006_bib29","doi-asserted-by":"crossref","first-page":"e855","DOI":"10.1111\/jdv.17581","article-title":"Three cases of vesiculobullous non\u2013IgE-mediated cutaneous reactions to tozinameran (Pfizer-BioNTech COVID-19 vaccine)","volume":"35","author":"Juay","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.02.006_bib30","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.oooo.2021.06.019","article-title":"Stevens-Johnson syndrome post second dose of Pfizer COVID-19 vaccine: a case report","volume":"132","author":"Elboraey","year":"2021","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.jaip.2025.02.006_bib31","first-page":"180","article-title":"An unusual presentation of Steven-Johnson syndrome after Bnt162b2 COVID-19 vaccination","volume":"35","author":"Patel","year":"2023","journal-title":"J\u00a0Ayub Med Coll Abbottabad"},{"key":"10.1016\/j.jaip.2025.02.006_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.19065","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis overlap case possibly induced by COVID-19 vaccine","author":"Cenk","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.02.006_bib33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1089\/derm.2022.29003.msj","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis overlap after the third dose of BNT162b2 mRNA COVID-19 vaccination and literature review","volume":"34","author":"Jue","year":"2023","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaip.2025.02.006_bib34","first-page":"e17215","article-title":"Toxic epidermal necrolysis post COVID-19 vaccination\u2014first reported case","volume":"13","author":"Bakir","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2025.02.006_bib35","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/1346-8138.16808","article-title":"Rapidly progressing generalized bullous fixed drug eruption after the first dose of COVID-19 messenger RNA vaccination","volume":"50","author":"Choi","year":"2023","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib36","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1111\/jdv.17988","article-title":"Stevens-Johnson syndrome induced by Vaxvetria (AZD1222) COVID-19 vaccine","volume":"36","author":"Aimo","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.02.006_bib37","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/ced.14784","article-title":"COVID-19 vaccine\u2013induced Stevens-Johnson syndrome","volume":"46","author":"Dash","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib38","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1111\/ajd.13742","article-title":"A\u00a0case of toxic epidermal necrolysis after ChAdOx1 nCov-19 (AZD1222) vaccination","volume":"63","author":"Kherlopian","year":"2022","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib39","doi-asserted-by":"crossref","first-page":"e847","DOI":"10.1111\/jdv.17578","article-title":"Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature","volume":"35","author":"Annabi","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.02.006_bib40","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3904\/kjim.2021.198","article-title":"COVID-19 vaccine\u2013induced acute generalized exanthematous pustulosis","volume":"36","author":"Kang","year":"2021","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jaip.2025.02.006_bib41","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1111\/jdv.18059","article-title":"Another case of generalized bullous fixed drug eruption following an adenoviral vector\u2013based COVID-19 vaccine (ChAdOx1 nCov-19)","volume":"36","author":"Ben Salem","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.02.006_bib42","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/ced.14926","article-title":"Generalized bullous fixed drug eruption after Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccination","volume":"47","author":"Wantavornprasert","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jdcr.2021.11.028","article-title":"Drug reaction with eosinophilia and systemic symptoms syndrome following vaccination with the AstraZeneca COVID-19 vaccine","volume":"20","author":"O'Connor","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaip.2025.02.006_bib44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jdcr.2021.05.010","article-title":"A\u00a0case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine","volume":"13","author":"Lospinoso","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaip.2025.02.006_bib45","doi-asserted-by":"crossref","first-page":"e15416","DOI":"10.1111\/dth.15416","article-title":"An extremely rare mucocutaneous adverse reaction following COVID-19 vaccination: toxic epidermal necrolysis","volume":"35","author":"Mardani","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaip.2025.02.006_bib46","doi-asserted-by":"crossref","first-page":"e15651","DOI":"10.1111\/dth.15651","article-title":"Cutaneous manifestations following COVID-19 vaccination: a report of 25 cases","volume":"35","author":"Shakoei","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaip.2025.02.006_bib47","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.reval.2022.07.001","article-title":"Lethal toxic epidermal necrolysis probably induced by Sinopharm COVID-19 vaccine","volume":"62","author":"Seck","year":"2022","journal-title":"Rev Fr Allergol (2009)"},{"key":"10.1016\/j.jaip.2025.02.006_bib48","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.jfo.2021.12.005","article-title":"Sinopharm COVID-19 vaccine\u2013induced Stevens-Johnson syndrome","volume":"45","author":"Boualila","year":"2022","journal-title":"J\u00a0Fr Ophtalmol"},{"key":"10.1016\/j.jaip.2025.02.006_bib49","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/jocd.14756","article-title":"A\u00a0case of Steven-Johnson syndrome after COVID-19 vaccination","volume":"21","author":"Mansouri","year":"2022","journal-title":"J\u00a0Cosmet Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib50","doi-asserted-by":"crossref","first-page":"S392","DOI":"10.1016\/j.ekir.2022.01.942","article-title":"Adverse events following immunisation (AEFI) of COVID-19 vaccines in kidney patients\u2014a case series","volume":"7","author":"Tsuew","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jaip.2025.02.006_bib51","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/joim.12150","article-title":"Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up","volume":"275","author":"Persson","year":"2014","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jaip.2025.02.006_bib52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/pds.4349","article-title":"The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: a Vaccine Safety Datalink study","volume":"27","author":"Daley","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaip.2025.02.006_bib53","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1684\/ejd.2011.1314","article-title":"Stevens-Johnson syndrome triggered by seasonal influenza vaccination and flucloxacillin: a pathogenetic hypothesis","volume":"21","author":"Fleming","year":"2011","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib54","doi-asserted-by":"crossref","first-page":"e68231","DOI":"10.1371\/journal.pone.0068231","article-title":"Stevens-Johnson syndrome associated with drugs and vaccines in children: a case-control study","volume":"8","author":"Raucci","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2025.02.006_bib55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/0018578717739727","volume":"53","author":"Mancano","year":"2018","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.jaip.2025.02.006_bib56","first-page":"e9405","article-title":"Stevens-Johnson syndrome due to influenza vaccination","volume":"12","author":"Tong","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2025.02.006_bib57","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jdcr.2022.02.002","article-title":"Stevens-Johnson syndrome in a pregnant woman who received the influenza vaccine","volume":"23","author":"Calley","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaip.2025.02.006_bib58","first-page":"A6710","article-title":"Obliterative bronchitis and bronchiolitis after toxic epidermal necrolysis","volume":"197","author":"O\u2019Connor","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.02.006_bib59","doi-asserted-by":"crossref","first-page":"274","DOI":"10.18176\/jiaci.0169","article-title":"Stevens-Johnson syndrome after influenza vaccine injection","volume":"27","author":"Oda","year":"2017","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2025.02.006_bib60","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jdcr.2018.07.013","article-title":"Generalized bullous fixed-drug eruption secondary to the influenza vaccine","volume":"4","author":"Byrd","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaip.2025.02.006_bib61","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/000155501317208534","article-title":"Generalized bullous fixed drug eruption after influenza vaccination, simulating bullous pemphigoid","volume":"81","author":"Garcia-Doval","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2025.02.006_bib62","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5694\/mja2.50519","article-title":"A\u00a0case of drug reaction with eosinophilia and systemic symptoms (DRESS) without a typical precipitant","volume":"212","author":"Griffin","year":"2020","journal-title":"Med J Aust"},{"key":"10.1016\/j.jaip.2025.02.006_bib63","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/1346-8138.13487","article-title":"Influenza vaccine\u2013induced acute generalized exanthematous pustulosis during pregnancy","volume":"44","author":"Matsuo","year":"2017","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib64","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0264-410X(00)00297-8","article-title":"The postmarketing safety profile of varicella vaccine","volume":"19","author":"Sharrar","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.jaip.2025.02.006_bib65","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.284.10.1271","article-title":"Postlicensure safety surveillance for varicella vaccine","volume":"284","author":"Wise","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2025.02.006_bib66","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00006454-200102000-00022","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the Vaccine Adverse Event Reporting System","volume":"20","author":"Ball","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaip.2025.02.006_bib67","doi-asserted-by":"crossref","first-page":"240","DOI":"10.5694\/mja11.11484","article-title":"Stevens-Johnson syndrome after varicella vaccination","volume":"196","author":"Christou","year":"2012","journal-title":"Med J Aust"},{"key":"10.1016\/j.jaip.2025.02.006_bib68","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archderm.1974.01630110060017","article-title":"Toxic epidermal necrolysis following measles vaccination","volume":"110","author":"Shoss","year":"1974","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib69","first-page":"264","article-title":"Stevens-Johnson syndrome following measles vaccination","volume":"47","author":"Hazir","year":"1997","journal-title":"J\u00a0Pak Med Assoc"},{"key":"10.1016\/j.jaip.2025.02.006_bib70","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/00006454-200012000-00002","article-title":"Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up","volume":"19","author":"Patja","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaip.2025.02.006_bib71","first-page":"59","article-title":"Toxic epidermal necrolysis following morbilli-parotitis-rubella vaccination","volume":"13","author":"Dobrosavljevic","year":"1999","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.02.006_bib72","doi-asserted-by":"crossref","first-page":"B46","DOI":"10.1016\/j.vaccine.2011.12.112","article-title":"Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010","volume":"30","author":"Ouandaogo","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jaip.2025.02.006_bib73","doi-asserted-by":"crossref","DOI":"10.5070\/D3241037941","article-title":"Vaccine-induced toxic epidermal necrolysis: a case and systematic review","volume":"24","author":"Chahal","year":"2018","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaip.2025.02.006_bib74","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0025-6196(11)62605-0","article-title":"Stevens-Johnson syndrome after immunization with smallpox, anthrax, and tetanus vaccines","volume":"79","author":"Chopra","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaip.2025.02.006_bib75","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bcp.13512","article-title":"First case of Stevens-Johnson syndrome after rabies vaccination","volume":"84","author":"Ma","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2025.02.006_bib76","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1590\/abd1806-4841.20188237","article-title":"Toxic epidermal necrolysis after yellow fever vaccination","volume":"93","author":"Flora","year":"2018","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib77","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3349\/ymj.2012.53.1.228","article-title":"Toxic epidermal necrolysis with ocular involvement following vaccination for hemorrhagic fever with renal syndrome","volume":"53","author":"Hwang","year":"2012","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.jaip.2025.02.006_bib78","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.vaccine.2019.12.028","article-title":"Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999\u20132017","volume":"38","author":"Su","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jaip.2025.02.006_bib79","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1542\/peds.2008-1923","article-title":"Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis","volume":"123","author":"Levi","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaip.2025.02.006_bib80","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaci.2015.07.048","article-title":"Risk of anaphylaxis after vaccination in children and adults","volume":"137","author":"McNeil","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.02.006_bib81","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jaip.2021.01.022","article-title":"The COVID-19 pandemic in 2021: avoiding overdiagnosis of anaphylaxis risk while safely vaccinating the world","volume":"9","author":"Greenhawt","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.006_bib82","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jaip.2025.02.006_bib83","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: a review on adjuvants in licensed vaccines","volume":"39","author":"Del Giudice","year":"2018","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jaip.2025.02.006_bib84","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-024-00514-0","article-title":"Severe cutaneous adverse reactions","volume":"10","author":"Hung","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaip.2025.02.006_bib86","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1089\/wound.2019.0977","article-title":"Toxic epidermal necrolysis and Steven-Johnson syndrome: a comprehensive review","volume":"9","author":"Charlton","year":"2020","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"10.1016\/j.jaip.2025.02.006_bib87","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2020.09.024","article-title":"Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis","volume":"87","author":"Hadavand","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib88","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.clindermatol.2020.06.008","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"38","author":"Cardones","year":"2020","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib89","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2013.11.015","article-title":"Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome\/toxic epidermal necrolysis by immunohistopathological features","volume":"70","author":"Cho","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib90","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib91","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib92","first-page":"743","article-title":"High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases","volume":"20","author":"Chen","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.006_bib93","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ophtha.2024.03.023","article-title":"Post hoc analysis of role of etanercept in ocular sequelae of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"131","author":"Pan","year":"2024","journal-title":"Ophthalmology"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825001692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825001692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T23:12:45Z","timestamp":1753225965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825001692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2213219825001692"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.02.006","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe Cutaneous Adverse Reactions Following Vaccination: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}